illiam Blair slashed its price target for aTyr Pharma (NASDAQ:LIFE) to $4 from $8 but maintained its “market perform” rating after the company released data from three Phase 1/2 studies of Resolaris in rare muscle diseases. The stock closed at $2.80 on Dec. 13.Read More
William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday.Read More
William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN).
Under the accord, Arrowhead would receive an up-front fee of $35-million and $21.5-million in equity, and up to $617-million in options and milestones, plus royalties.Read More
William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier.
“Curing chronic hepatitis B infections is the next frontier after solving the hepatitis C problem, and the markets for both disease cures could be similar in size, reaching $200-billion each in cumulative global sales over a span of two decades,” writes analyst Katherine Xu.Read More
William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday.
“We note that AFFINITY is the key study of the lead asset, custirsen, as a chemotherapy companion in the second-line chemo setting in metastatic castration resistant prostate cancer,” writes analyst Katherine Xu.Read More
William Blair lowered its price target for Synthetic Biologics (NYSE:SYN) to $7 from $10, citing potential delays to commercialize the company’s two programs. The stock closed at $1.67 on Wednesday.Read More
William Blair has raised it price target for ARIAD Pharmaceuticals (NASDAQ:ARIA) to $12 from $10 after an analyst day on Friday where the company discussed the outcome of its strategic review. The stock was quoted at $7.59 on Monday afternoon.
The strategic review included ARIAD’s commitment to financial discipline and its refined focus on rare cancers with precision medicines in Iclusig, brigatinib, and AP32788, as well as discovery work on a suite of oral agents in immuno-oncology.Read More